clinical lab test references
support@biomarkerslabs.com
BiomarkersLabs.com

Lab Testing for Practitioners

BML-CAR-002cardiovascularUSA

Triglycerides Test

The triglycerides test measures the principal storage lipids transported in chylomicrons and VLDL. Triglycerides contribute to cardiovascular risk, are a sensitive marker of insulin resistance and metabolic syndrome, and at very high levels — above roughly 500 mg/dL — pose a direct risk of acute pancreatitis.

1

Biomarkers

Blood (serum)

Sample

1–2 business days

Turnaround

Fasting 9–12 hours is preferred for reliable triglycerides, particularly when the value is being used for calculated LDL-C or to characterise hypertriglyceridaemia; non-fasting measurement is increasingly accepted for routine screening

Fasting

What is the Triglycerides test?

The Triglycerides Test measures serum triglycerides, the principal storage lipids transported in chylomicrons and VLDL. It contributes to cardiovascular risk assessment, serves as a sensitive marker of metabolic dysfunction and insulin resistance, and — at high concentrations — identifies patients at risk of acute pancreatitis. Within lipid and metabolic assessment, triglycerides carry a dual significance that distinguishes them from the other lipid fractions. As a cardiovascular marker they contribute to risk but are less directly a treatment target than LDL-C and non-HDL-C, and their independent atherogenic contribution is best captured through non-HDL cholesterol and ApoB. As a metabolic marker they are among the earliest abnormalities in insulin resistance and metabolic syndrome, frequently paired with a low HDL-C. And separately from atherosclerosis, very high triglycerides pose a direct risk of acute pancreatitis requiring specific management. They are also the input that determines whether calculated LDL-C is valid. For these reasons triglycerides are usually interpreted within the full lipid panel and the wider metabolic picture rather than in isolation.

What does the Triglycerides test measure?

1
TG(Triglycerides)
Range: Normal: <150 mg/dL (<1.7 mmol/L); borderline high: 150–199 mg/dL; high: 200–499 mg/dL; very high: ≥500 mg/dL (pancreatitis risk) # REVIEWER FLAG: Thresholds and fasting versus non-fasting interpretation are guideline-dependent — reviewer to confirm framing and units.Optimal: <100 mg/dL is sometimes cited as optimal # REVIEWER FLAG: 'Optimal' triglyceride threshold below standard cut-offs is context-dependent — reviewer to confirm framing.mg/dL / mmol/L

Triglycerides are the principal storage lipids, composed of three fatty acids esterified to glycerol and transported in chylomicrons after a meal and in VLDL synthesised by the liver. Serum triglycerides rise markedly after eating, which is why fasting samples have traditionally been used, and they are strongly influenced by carbohydrate and alcohol intake, adiposity, and insulin resistance. Very high concentrations reflect impaired clearance of triglyceride-rich lipoproteins and carry a risk of acute pancreatitis independent of atherosclerotic risk.

Triglycerides contribute to cardiovascular risk assessment and are a sensitive marker of metabolic dysfunction and insulin resistance, often the earliest lipid abnormality in metabolic syndrome. They are also required for the Friedewald calculation of LDL-C, which becomes invalid above roughly 400 mg/dL. Distinct from atherosclerotic risk, markedly elevated triglycerides (above about 500 mg/dL, and especially above 1000 mg/dL) raise the risk of acute pancreatitis and warrant specific, often urgent, management.

Why is the Triglycerides test ordered?

  • Cardiovascular risk assessment as part of lipid evaluation, interpreted alongside LDL-C, HDL-C, and non-HDL-C
  • Assessment of metabolic syndrome, insulin resistance, or type 2 diabetes, where raised triglycerides with a low HDL-C is a characteristic pattern
  • Identification of very high triglycerides carrying a risk of acute pancreatitis, which requires specific and often urgent management
  • Evaluation of suspected hypertriglyceridaemia, including familial and secondary causes
  • Determination of whether calculated LDL-C is valid, since the Friedewald equation fails above roughly 400 mg/dL
  • Assessment of non-alcoholic fatty liver disease and related metabolic dysfunction where triglycerides are informative
  • Monitoring of response to dietary, lifestyle, or pharmacological intervention targeting triglycerides

Sample collection and turnaround

Sample type

Blood (serum)

Fasting required

Fasting 9–12 hours is preferred for reliable triglycerides, particularly when the value is being used for calculated LDL-C or to characterise hypertriglyceridaemia; non-fasting measurement is increasingly accepted for routine screening

Collection method

Venipuncture at patient service centre

Turnaround

1–2 business days

Collection notes

Advise fasting 9–12 hours and avoidance of alcohol beforehand where a reliable value is required. Defer during acute illness. Document medications, diabetes control, thyroid and renal status, and pregnancy, as secondary causes are common in marked hypertriglyceridaemia. Confirm markedly elevated values on a fasting sample.

Specimen requirements

Minimum 0.5 mL serum. Separate serum from cells per Access Medical Laboratories protocol. Specimen stable refrigerated; follow Access Medical Laboratories transport guidelines.

What can affect Triglycerides results?

elevatesNon-fasting state and recent meals

Triglycerides rise substantially after eating as chylomicrons enter the circulation, so a non-fasting sample gives a higher value. Fasting for 9–12 hours has traditionally been required, though non-fasting measurement is increasingly accepted for routine screening.

elevatesAlcohol intake

Recent alcohol consumption markedly raises triglycerides, so patients should avoid alcohol before testing to obtain a representative result. Chronic excess is a common cause of hypertriglyceridaemia.

elevatesCarbohydrate intake and insulin resistance

High carbohydrate intake, particularly refined carbohydrate and fructose, and insulin resistance both increase hepatic VLDL production and impair clearance, raising triglycerides.

elevatesUncontrolled diabetes and metabolic conditions

Poor glycaemic control, hypothyroidism, nephrotic syndrome, and chronic kidney disease raise triglycerides, so secondary causes should be sought and addressed in significant hypertriglyceridaemia.

elevatesMedications (oestrogens, corticosteroids, retinoids, some antiretrovirals, beta-blockers)

Several drug classes raise triglycerides, sometimes substantially. Medication history should be documented, particularly when investigating marked or unexplained hypertriglyceridaemia.

elevatesPregnancy

Triglycerides rise physiologically and substantially through pregnancy, so results are not interpreted against standard thresholds during gestation; marked elevations in pregnancy nonetheless carry pancreatitis risk.

What do Triglycerides results mean?

Elevated

Raised triglycerides indicate metabolic dysfunction and contribute to cardiovascular risk, and are commonly accompanied by a low HDL-C. Above roughly 400 mg/dL the Friedewald-calculated LDL-C becomes invalid, so direct LDL-C, non-HDL-C, or ApoB should be used. Above about 500 mg/dL, and particularly above 1000 mg/dL, the risk of acute pancreatitis rises and warrants specific, often urgent, management. Secondary causes — alcohol, uncontrolled diabetes, hypothyroidism, renal disease, medications — should be sought.

Normal

Triglycerides below 150 mg/dL are within the normal range. A normal value is reassuring metabolically, though cardiovascular risk still depends on the full lipid profile — particularly LDL-C and non-HDL-C — and the wider risk-factor picture.

Reduced

Low triglycerides are generally favourable and carry no recognised adverse significance. Very low values can occasionally accompany malnutrition, malabsorption, or hyperthyroidism.

Note: Triglycerides are strongly affected by fasting status, recent alcohol, and carbohydrate intake, so a single value may not be representative and marked elevations should be confirmed on a fasting sample. Their role is dual: a contributor to cardiovascular risk best captured through non-HDL-C and ApoB, and a direct pancreatitis risk at very high levels. They also determine whether calculated LDL-C is valid. Secondary causes should be sought in significant hypertriglyceridaemia, and results interpreted within the full lipid and metabolic picture.

Frequently asked questions

They contribute to cardiovascular risk and are a sensitive marker of metabolic dysfunction and insulin resistance, often the earliest lipid abnormality in metabolic syndrome. At very high levels they also pose a direct risk of acute pancreatitis.

How to access the Triglycerides test

The Triglycerides reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: June 2, 2026

Last reviewed: June 2, 2026

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.

Related tests

cardiovascular

Lipid Panel

The standard lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides, and derives non-HDL cholesterol, providing the core assessment of cardiovascular lipid risk. LDL-C is the principal treatment target and non-HDL-C an increasingly used secondary measure.

BML-CAR-001View reference →

cardiovascular

Direct LDL-C

The direct LDL cholesterol test measures LDL-C analytically rather than deriving it from the Friedewald calculation used in standard lipid panels. It is preferred where the calculation fails — when triglycerides exceed roughly 400 mg/dL, at very low LDL-C, and in non-fasting samples.

BML-CAR-028View reference →

cardiovascular

Apo-B

The Apolipoprotein B (Apo-B) test counts the total number of atherogenic lipoprotein particles, since each LDL, VLDL, IDL, and lipoprotein(a) particle carries one apolipoprotein B. It is a strong cardiovascular risk marker, in many analyses superior to LDL cholesterol because it captures particle number rather than cholesterol content, and is especially informative where LDL cholesterol…

BML-CAR-025View reference →